Holen Sie sich die Stockscreener-App
16.04
0.12%
-0.00
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
GLUE SEC FilingsMonte Rosa Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Monte Rosa Therapeutics (GLUE) Likely to Surpass Earnings Forecasts: Will the Share Price Rise? - Bitget
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Monte Rosa Therapeutics earnings on deck amid revenue decline - Investing.com
Assessing Monte Rosa Therapeutics (GLUE) Valuation After MRT-2359 Data Update And New Public Offering - Yahoo Finance
How Monte Rosa’s MRT-2359 Prostate Cancer Data and Funding Plans Could Shape GLUE’s Risk‑Reward Profile - Yahoo Finance
Is Monte Rosa Therapeutics Inc. stock attractive for income investors2026 Institutional Moves & Daily Growth Stock Tips - Naître et grandir
Profit Review: Will Monte Rosa Therapeutics Inc benefit from AI trendsJuly 2025 Breakouts & High Accuracy Trade Alerts - baoquankhu1.vn
What is Monte Rosa Therapeutics Incs market position2025 Momentum Check & Community Shared Stock Ideas - baoquankhu1.vn
Monte Rosa to focus on prostate cancer only for oncology asset MRT-2359 - MSN
Decliners Report: Is Monte Rosa Therapeutics Inc forming a bullish divergenceIPO Watch & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Dunn Edmund, principal accounting officer, sells Monte Rosa (GLUE) shares for $2496 - Investing.com India
Monte Rosa Therapeutics (NASDAQ:GLUE) CEO Markus Warmuth Sells 5,466 Shares - MarketBeat
Monte Rosa (GLUE) CEO Warmuth sells 5,466 shares under 10b5-1 plan - Stock Titan
GLUE (NASDAQ: GLUE) Rule 144 filing lists RSU vest and recent insider sales - Stock Titan
GLUE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Significant Increase in Short Interest - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Edmund Dunn Sells 25,164 Shares - MarketBeat
Edmund Dunn of Monte Rosa (GLUE) exercises options, sells 25,700 shares - Stock Titan
Markus Warmuth (GLUE) files Form 144 showing proposed sales and RSU dates - Stock Titan
Affiliate sale: GLUE (NASDAQ: GLUE) 536 shares via option exercise - Stock Titan
Monte Rosa Therapeutics CEO unveils pipeline progress at TD Cowen Health Care Conference - Traders Union
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Positive MRT-2359 Clinical Data Update - simplywall.st
What Monte Rosa Therapeutics (GLUE)'s Phase 1/2 MRT-2359 Combo Data Means For Shareholders - Sahm
Monte Rosa Therapeutics advances MRT-2359 into Phase 2 trial targeting AR mutations in mCRPC - Traders Union
Insider Sell: Filip Janku Sells Shares of Monte Rosa Therapeutics Inc (GLUE) - GuruFocus
GLUEMonte Rosa Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Monte Rosa Therapeutics (GLUE) CMO sells 9,189 shares in open market - Stock Titan
Monte Rosa shares rise on prostate cancer trial results By Investing.com - Investing.com South Africa
Monte Rosa shares rise on prostate cancer trial results - Investing.com India
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASC - The Manila Times
Filip Janku plans to sell 3,155 GLUE shares (NASDAQ: GLUE) - Stock Titan
Biotech firm Monte Rosa lines up three investor talks in March - Stock Titan
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - marketscreener.com
Does Monte Rosa Therapeutics Inc have pricing power2025 Buyback Activity & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Certain Restricted Stock Units of Monte Rosa Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-FEB-2026. - marketscreener.com
Certain Common Stock of Monte Rosa Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-FEB-2026. - marketscreener.com
What are Monte Rosa Therapeutics Inc.’s recent SEC filings showingWeekly Stock Recap & Stock Portfolio Risk Management - mfd.ru
Monte Rosa Therapeutics, Inc. $GLUE Shares Sold by GSA Capital Partners LLP - MarketBeat
Is Monte Rosa Therapeutics Inc. stock a top pick in earnings seasonAnalyst Downgrade & Weekly Momentum Picks - mfd.ru
BVF group discloses 5.9% Monte Rosa (NASDAQ: GLUE) ownership stake - Stock Titan
Portfolio Recap: Can Atomera Incorporated scale operations efficientlyEarnings Miss & Consistent Income Trade Ideas - baoquankhu1.vn
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Update - MarketBeat
The Market Doesn't Like What It Sees From Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) Revenues Yet As Shares Tumble 26% - simplywall.st
Does Monte Rosa Therapeutics Inc. have pricing power2025 Retail Activity & Free Community Consensus Stock Picks - mfd.ru
Is Monte Rosa Therapeutics Inc. forming a bullish divergenceWeekly Trade Summary & AI Based Buy/Sell Signal Reports - mfd.ru
Monte Rosa Therapeutics, Inc. Announces Executive Changes, Effective April 3, 2026 - marketscreener.com
Monte Rosa Therapeutics Announces Management Change - TradingView
Smart Money: How sensitive is Monte Rosa Therapeutics Inc to inflationEarnings Growth Report & Technical Buy Zone Confirmations - baoquankhu1.vn
3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher - Investing.com
Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) institutional investors lost 12% last week but have benefitted from longer-term gains - Yahoo Finance
Zacks Research Downgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to Hold - MarketBeat
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):